Physician profile
Steve Yang
NPI 1770070781
$12,158.03
in general payments reported to CMS, 2019-2025
26 companies · $2,271 in 2025
The $2,271 reported for 2025 was more than what 94% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $813 · 2022: $3,016 · 2023: $2,870 · 2024: $3,189 · 2025: $2,271.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,132 · Education: $197.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,132.46 |
| Education | $196.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $1,774.53 | 2021-2025 | Aristada, Lybalvi |
| Vanda Pharmaceuticals INC. | $1,362.55 | 2021-2025 | Fanapt, Hetlioz |
| Teva Pharmaceuticals USA, INC. | $1,288.64 | 2021-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Abbvie INC. | $1,179.72 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $1,010.13 | 2021-2025 | Ingrezza |
| Sunovion Pharmaceuticals INC. | $915.77 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $873.32 | 2021-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $652.37 | 2021-2025 | Invega Sustenna, Invega Trinza |
| Otsuka America Pharmaceutical, INC. | $561.83 | 2021-2025 | Rexulti, Abilify Asimtufii, Nuedexta |
| Idorsia Pharmaceuticals US INC | $460.04 | 2022-2024 | Quviviq |
| Lundbeck LLC | $388.13 | 2021-2024 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Indivior INC. | $246.11 | 2021-2023 | Perseris |
| Gilead Sciences, INC. | $238.10 | 2023-2025 | Yeztugo, Veklury |
| E.R. Squibb & Sons, L.L.C. | $223.03 | 2024-2025 | Cobenfy |
| Axsome Therapeutics, INC. | $181.32 | 2023-2025 | Auvelity |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $167.63 | 2021-2024 | Loreev Xr |
| Eisai INC. | $149.95 | 2022-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $142.56 | 2021-2025 | Trintellix |
| Shionogi INC | $121.82 | 2022 | |
| Supernus Pharmaceuticals, INC. | $84.84 | 2022-2023 | Qelbree |
| Corium, LLC | $26.84 | 2024 | Azstarys |
| Neuronetics, INC. | $26.43 | 2022 | |
| Bioxcel Therapeutics, INC. | $20.83 | 2023 | Igalmi |
| Owp Pharmaceuticals, INC. | $20.80 | 2023 | Lamotrigine, Subvenite |
| Noven Therapeutics, LLC | $20.62 | 2022 | |
| Merck Sharp & Dohme LLC | $20.12 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steve Yang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.